Braydon Dymm, MD
@befast.bsky.social
Stroke Neurologist. The brain is fascinating 🧠
Pinned
Braydon Dymm, MD
@befast.bsky.social
· Dec 17
2025 was a landmark year for stroke neurology.
From the MeVO trials to news of AI-driven systems of care and Factor XIa inhibitors on the horizon, the landscape of vascular neurology has shifted.
Here's a month-by-month recap of the year! 🧵
From the MeVO trials to news of AI-driven systems of care and Factor XIa inhibitors on the horizon, the landscape of vascular neurology has shifted.
Here's a month-by-month recap of the year! 🧵
Reposted by Braydon Dymm, MD
Millions of people are turning to #AI chatbots for mental health support, but is it safe and regulated?
Here’s what experts have to say. ja.ma/4pEidSB
Here’s what experts have to say. ja.ma/4pEidSB
The Rise of Therapy Chatbots
This Medical News article discusses the growing use of generative artificial intelligence chatbots as sources of mental health support.
ja.ma
January 11, 2026 at 3:00 PM
Millions of people are turning to #AI chatbots for mental health support, but is it safe and regulated?
Here’s what experts have to say. ja.ma/4pEidSB
Here’s what experts have to say. ja.ma/4pEidSB
That’s a strong headline. Can it really be that easy?
January 10, 2026 at 2:24 PM
That’s a strong headline. Can it really be that easy?
Reposted by Braydon Dymm, MD
Fun (and educational?!) little game about cerebral vascular anatomy and stroke presentations by @mettermd.bsky.social and inspired by @befast.bsky.social. 🤩 I'm jealous!
The Circle of Thrillis!
micahetter.me/CircleOfThri...
The Circle of Thrillis!
micahetter.me/CircleOfThri...
Circle of Thrillis: Clot Busters
micahetter.me
January 9, 2026 at 4:58 AM
Fun (and educational?!) little game about cerebral vascular anatomy and stroke presentations by @mettermd.bsky.social and inspired by @befast.bsky.social. 🤩 I'm jealous!
The Circle of Thrillis!
micahetter.me/CircleOfThri...
The Circle of Thrillis!
micahetter.me/CircleOfThri...
Reposted by Braydon Dymm, MD
Utah is the first state to allow AI to renew prescriptions without doctor involvement
www.politico.com/news/2026/01...
www.politico.com/news/2026/01...
Artificial intelligence begins prescribing medications in Utah
Pilot program will test how far patients and regulators are willing to trust AI in medicine.
www.politico.com
January 6, 2026 at 11:44 PM
Utah is the first state to allow AI to renew prescriptions without doctor involvement
www.politico.com/news/2026/01...
www.politico.com/news/2026/01...
2025 proved that stroke care continues to evolve.
Which of these trials changed your practice the most this year? Let's discuss.
Which of these trials changed your practice the most this year? Let's discuss.
December 17, 2025 at 9:02 PM
2025 proved that stroke care continues to evolve.
Which of these trials changed your practice the most this year? Let's discuss.
Which of these trials changed your practice the most this year? Let's discuss.
December: AI Scaling Across Systems
We end the year with real-world evidence. The NHS/Brainomix data (Lancet Digital Health) showed that AI imaging support, deployed at a national scale, increases thrombectomy rates and reduces "postcode lotteries" in stroke care.
We end the year with real-world evidence. The NHS/Brainomix data (Lancet Digital Health) showed that AI imaging support, deployed at a national scale, increases thrombectomy rates and reduces "postcode lotteries" in stroke care.
December 17, 2025 at 9:02 PM
December: AI Scaling Across Systems
We end the year with real-world evidence. The NHS/Brainomix data (Lancet Digital Health) showed that AI imaging support, deployed at a national scale, increases thrombectomy rates and reduces "postcode lotteries" in stroke care.
We end the year with real-world evidence. The NHS/Brainomix data (Lancet Digital Health) showed that AI imaging support, deployed at a national scale, increases thrombectomy rates and reduces "postcode lotteries" in stroke care.
November: CREST-2 and the Carotid Debate
Results from CREST-2 (NEJM) at #SVIN25 bolstered the role of stenting alongside intensive medical management for asymptomatic carotid stenosis. The role of CEA is being questioned.
Results from CREST-2 (NEJM) at #SVIN25 bolstered the role of stenting alongside intensive medical management for asymptomatic carotid stenosis. The role of CEA is being questioned.
December 17, 2025 at 9:02 PM
November: CREST-2 and the Carotid Debate
Results from CREST-2 (NEJM) at #SVIN25 bolstered the role of stenting alongside intensive medical management for asymptomatic carotid stenosis. The role of CEA is being questioned.
Results from CREST-2 (NEJM) at #SVIN25 bolstered the role of stenting alongside intensive medical management for asymptomatic carotid stenosis. The role of CEA is being questioned.
October: Redemption of the FXIa Class
At #WSC2025, OCEANIC-STROKE provided a major win the class desperately needed. Unlike the AF trial, asundexian in secondary prevention hit its mark. We're all eagerly awaiting the full publication.
At #WSC2025, OCEANIC-STROKE provided a major win the class desperately needed. Unlike the AF trial, asundexian in secondary prevention hit its mark. We're all eagerly awaiting the full publication.
December 17, 2025 at 9:02 PM
October: Redemption of the FXIa Class
At #WSC2025, OCEANIC-STROKE provided a major win the class desperately needed. Unlike the AF trial, asundexian in secondary prevention hit its mark. We're all eagerly awaiting the full publication.
At #WSC2025, OCEANIC-STROKE provided a major win the class desperately needed. Unlike the AF trial, asundexian in secondary prevention hit its mark. We're all eagerly awaiting the full publication.
September: Reality Check for ICH Surgery
The MIND trial (JAMA) provided a sobering follow-up to last year’s ENRICH. Using the Artemis system, it was neutral for its primary endpoint (180-day mRS). Seems the deeper bleeds have less treatment-related recovery potential.
The MIND trial (JAMA) provided a sobering follow-up to last year’s ENRICH. Using the Artemis system, it was neutral for its primary endpoint (180-day mRS). Seems the deeper bleeds have less treatment-related recovery potential.
December 17, 2025 at 9:02 PM
September: Reality Check for ICH Surgery
The MIND trial (JAMA) provided a sobering follow-up to last year’s ENRICH. Using the Artemis system, it was neutral for its primary endpoint (180-day mRS). Seems the deeper bleeds have less treatment-related recovery potential.
The MIND trial (JAMA) provided a sobering follow-up to last year’s ENRICH. Using the Artemis system, it was neutral for its primary endpoint (180-day mRS). Seems the deeper bleeds have less treatment-related recovery potential.
August: Pushing the Alteplase Window
The HOPE trial (JAMA) challenged the 4.5-hour limit. In selected patients with salvageable penumbra (4.5–24h window), late-window alteplase showed significant functional benefit. Compare & contrast to negative TIMELESS trial.
The HOPE trial (JAMA) challenged the 4.5-hour limit. In selected patients with salvageable penumbra (4.5–24h window), late-window alteplase showed significant functional benefit. Compare & contrast to negative TIMELESS trial.
December 17, 2025 at 9:02 PM
August: Pushing the Alteplase Window
The HOPE trial (JAMA) challenged the 4.5-hour limit. In selected patients with salvageable penumbra (4.5–24h window), late-window alteplase showed significant functional benefit. Compare & contrast to negative TIMELESS trial.
The HOPE trial (JAMA) challenged the 4.5-hour limit. In selected patients with salvageable penumbra (4.5–24h window), late-window alteplase showed significant functional benefit. Compare & contrast to negative TIMELESS trial.
July: Tirofiban as a Potent Adjunct
The ASSET-IT trial (NEJM) showed early tirofiban administration after IV thrombolysis improved functional outcomes without a prohibitive increase in symptomatic ICH. Unclear how to interpret in light of negative MOST trial (eptifibatide).
The ASSET-IT trial (NEJM) showed early tirofiban administration after IV thrombolysis improved functional outcomes without a prohibitive increase in symptomatic ICH. Unclear how to interpret in light of negative MOST trial (eptifibatide).
December 17, 2025 at 9:02 PM
July: Tirofiban as a Potent Adjunct
The ASSET-IT trial (NEJM) showed early tirofiban administration after IV thrombolysis improved functional outcomes without a prohibitive increase in symptomatic ICH. Unclear how to interpret in light of negative MOST trial (eptifibatide).
The ASSET-IT trial (NEJM) showed early tirofiban administration after IV thrombolysis improved functional outcomes without a prohibitive increase in symptomatic ICH. Unclear how to interpret in light of negative MOST trial (eptifibatide).
June: Early DOAC Restart is Safe & Effective
Time to abandon the 3-6-12 day rule? The CATALYST IPD meta-analysis (Lancet) suggests we should. Early DOAC initiation after AF-related stroke was supported by pooled data, reducing the "vulnerable window" for recurrent emboli.
Time to abandon the 3-6-12 day rule? The CATALYST IPD meta-analysis (Lancet) suggests we should. Early DOAC initiation after AF-related stroke was supported by pooled data, reducing the "vulnerable window" for recurrent emboli.
December 17, 2025 at 9:02 PM
June: Early DOAC Restart is Safe & Effective
Time to abandon the 3-6-12 day rule? The CATALYST IPD meta-analysis (Lancet) suggests we should. Early DOAC initiation after AF-related stroke was supported by pooled data, reducing the "vulnerable window" for recurrent emboli.
Time to abandon the 3-6-12 day rule? The CATALYST IPD meta-analysis (Lancet) suggests we should. Early DOAC initiation after AF-related stroke was supported by pooled data, reducing the "vulnerable window" for recurrent emboli.
May: AI Moves from Hype to Outcomes
At #ESOC2025, the GOLDEN BRIDGE II trial demonstrated that AI decision support provides faster reads and actually improves guideline adherence and patient outcomes.
At #ESOC2025, the GOLDEN BRIDGE II trial demonstrated that AI decision support provides faster reads and actually improves guideline adherence and patient outcomes.
December 17, 2025 at 9:02 PM
May: AI Moves from Hype to Outcomes
At #ESOC2025, the GOLDEN BRIDGE II trial demonstrated that AI decision support provides faster reads and actually improves guideline adherence and patient outcomes.
At #ESOC2025, the GOLDEN BRIDGE II trial demonstrated that AI decision support provides faster reads and actually improves guideline adherence and patient outcomes.
April: Posterior Circulation Windows Open
The EXPECTS trial (NEJM) provided preliminary evidence that the extended window may be safely and effectively extended in posterior circulation strokes. Confirmatory trials in more diverse populations needed.
The EXPECTS trial (NEJM) provided preliminary evidence that the extended window may be safely and effectively extended in posterior circulation strokes. Confirmatory trials in more diverse populations needed.
December 17, 2025 at 9:02 PM
April: Posterior Circulation Windows Open
The EXPECTS trial (NEJM) provided preliminary evidence that the extended window may be safely and effectively extended in posterior circulation strokes. Confirmatory trials in more diverse populations needed.
The EXPECTS trial (NEJM) provided preliminary evidence that the extended window may be safely and effectively extended in posterior circulation strokes. Confirmatory trials in more diverse populations needed.
March: The TNK Revolution is Official
A long-awaited milestone: The FDA officially approved Tenecteplase (TNKase) for acute ischemic stroke. The transition from alteplase pumps to the "one-and-done" bolus is now the standard of care across US stroke centers.
A long-awaited milestone: The FDA officially approved Tenecteplase (TNKase) for acute ischemic stroke. The transition from alteplase pumps to the "one-and-done" bolus is now the standard of care across US stroke centers.
December 17, 2025 at 9:02 PM
March: The TNK Revolution is Official
A long-awaited milestone: The FDA officially approved Tenecteplase (TNKase) for acute ischemic stroke. The transition from alteplase pumps to the "one-and-done" bolus is now the standard of care across US stroke centers.
A long-awaited milestone: The FDA officially approved Tenecteplase (TNKase) for acute ischemic stroke. The transition from alteplase pumps to the "one-and-done" bolus is now the standard of care across US stroke centers.
February: Reality Check for MeVO
The "MeVO" hype met clinical reality at #ISC25. ESCAPE-MeVO, DISCOUNT, and DISTAL all returned neutral results. While we can technically reach distal occlusions, the benefit of EVT remains elusive compared to medical management.
The "MeVO" hype met clinical reality at #ISC25. ESCAPE-MeVO, DISCOUNT, and DISTAL all returned neutral results. While we can technically reach distal occlusions, the benefit of EVT remains elusive compared to medical management.
December 17, 2025 at 9:02 PM
February: Reality Check for MeVO
The "MeVO" hype met clinical reality at #ISC25. ESCAPE-MeVO, DISCOUNT, and DISTAL all returned neutral results. While we can technically reach distal occlusions, the benefit of EVT remains elusive compared to medical management.
The "MeVO" hype met clinical reality at #ISC25. ESCAPE-MeVO, DISCOUNT, and DISTAL all returned neutral results. While we can technically reach distal occlusions, the benefit of EVT remains elusive compared to medical management.
January: The Factor XI Era Arrives
AZALEA–TIMI 71 (NEJM) set the tone for the year. Abelacimab showed a massive reduction in bleeding compared to rivaroxaban in patients with AFib. Still waiting on efficacy!
AZALEA–TIMI 71 (NEJM) set the tone for the year. Abelacimab showed a massive reduction in bleeding compared to rivaroxaban in patients with AFib. Still waiting on efficacy!
December 17, 2025 at 9:02 PM
January: The Factor XI Era Arrives
AZALEA–TIMI 71 (NEJM) set the tone for the year. Abelacimab showed a massive reduction in bleeding compared to rivaroxaban in patients with AFib. Still waiting on efficacy!
AZALEA–TIMI 71 (NEJM) set the tone for the year. Abelacimab showed a massive reduction in bleeding compared to rivaroxaban in patients with AFib. Still waiting on efficacy!
2025 was a landmark year for stroke neurology.
From the MeVO trials to news of AI-driven systems of care and Factor XIa inhibitors on the horizon, the landscape of vascular neurology has shifted.
Here's a month-by-month recap of the year! 🧵
From the MeVO trials to news of AI-driven systems of care and Factor XIa inhibitors on the horizon, the landscape of vascular neurology has shifted.
Here's a month-by-month recap of the year! 🧵
December 17, 2025 at 9:02 PM
2025 was a landmark year for stroke neurology.
From the MeVO trials to news of AI-driven systems of care and Factor XIa inhibitors on the horizon, the landscape of vascular neurology has shifted.
Here's a month-by-month recap of the year! 🧵
From the MeVO trials to news of AI-driven systems of care and Factor XIa inhibitors on the horizon, the landscape of vascular neurology has shifted.
Here's a month-by-month recap of the year! 🧵
KO KO KO merry Christmas!
December 15, 2025 at 12:27 AM
KO KO KO merry Christmas!
Dear everyone,
Please stop calling it a “mini-stroke”
Thanks In Advance
Please stop calling it a “mini-stroke”
Thanks In Advance
December 14, 2025 at 9:53 PM
Dear everyone,
Please stop calling it a “mini-stroke”
Thanks In Advance
Please stop calling it a “mini-stroke”
Thanks In Advance
Reposted by Braydon Dymm, MD
Cool new paper out in Nature on AI-designed proteins that survive 150 °C and nanonewton forces! www.nature.com/articles/s41...
It's very interesting work - but I see people saying it is also directly worrying. I disagree - to explain, here's a short 🧵
It's very interesting work - but I see people saying it is also directly worrying. I disagree - to explain, here's a short 🧵
Computational design of superstable proteins through maximized hydrogen bonding - Nature Chemistry
Nature contains a variety of mechanostable proteins, which all bear extensive hydrogen-bond networks within their β-sheet architectures to sustain high stability under stress. Now through integrating ...
www.nature.com
December 14, 2025 at 8:21 AM
Cool new paper out in Nature on AI-designed proteins that survive 150 °C and nanonewton forces! www.nature.com/articles/s41...
It's very interesting work - but I see people saying it is also directly worrying. I disagree - to explain, here's a short 🧵
It's very interesting work - but I see people saying it is also directly worrying. I disagree - to explain, here's a short 🧵
Here is the full translation of case 6.
December 13, 2025 at 10:52 PM
Here is the full translation of case 6.
The Edwin Smith Papyrus (c. 1600 BCE) is the oldest known surgical text and the first to mention the brain.
It links head injury to neurologic deficits and even describes CSF.
It links head injury to neurologic deficits and even describes CSF.
December 13, 2025 at 10:52 PM
The Edwin Smith Papyrus (c. 1600 BCE) is the oldest known surgical text and the first to mention the brain.
It links head injury to neurologic deficits and even describes CSF.
It links head injury to neurologic deficits and even describes CSF.
Reposted by Braydon Dymm, MD
Introducing NeuroDiscoveryBench, the first benchmark designed to test AI systems on real neuroscience data analysis. Built by @ai2.bsky.social using our high-quality, open datasets to accelerate brain science and AI-assisted discovery.
More: https://bit.ly/4rU5gWZ
Data: https://bit.ly/4iRMXh3
More: https://bit.ly/4rU5gWZ
Data: https://bit.ly/4iRMXh3
NeuroDiscoveryBench: Benchmarking AI for neuroscience data analysis | Ai2
NeuroDiscoveryBench is a benchmark to test how well AI systems can answer questions grounded in real-world neuroscience data.
allenai.org
December 12, 2025 at 11:34 PM
Introducing NeuroDiscoveryBench, the first benchmark designed to test AI systems on real neuroscience data analysis. Built by @ai2.bsky.social using our high-quality, open datasets to accelerate brain science and AI-assisted discovery.
More: https://bit.ly/4rU5gWZ
Data: https://bit.ly/4iRMXh3
More: https://bit.ly/4rU5gWZ
Data: https://bit.ly/4iRMXh3